Cargando…
Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis
The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or moderate COVID-19 patients. This meta-analysis was reported according to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Two authors independently performed a comprehensive s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239651/ https://www.ncbi.nlm.nih.gov/pubmed/37284377 http://dx.doi.org/10.7759/cureus.38586 |
_version_ | 1785053534960484352 |
---|---|
author | Benaicha, Karima Khenhrani, Raja Ram Veer, Maha Devi, Sapna Shahbaz, Usman Salah, Qais M Hammad, Mostafa Palleti, Sujith K |
author_facet | Benaicha, Karima Khenhrani, Raja Ram Veer, Maha Devi, Sapna Shahbaz, Usman Salah, Qais M Hammad, Mostafa Palleti, Sujith K |
author_sort | Benaicha, Karima |
collection | PubMed |
description | The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or moderate COVID-19 patients. This meta-analysis was reported according to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Two authors independently performed a comprehensive search for relevant studies in PubMed, Cochrane Library, and Web of Science. The keywords used to search for relevant records were “Molnupiravir,” “COVID-19,” and “efficacy.” This meta-analysis included studies that compared the effectiveness of molnupiravir with a placebo for COVID-19 treatment. The primary outcome assessed in this meta-analysis was the composite of hospitalization and all-cause mortality (30 days). In addition, we assessed all-cause mortality and hospitalization separately and the number of patients who tested negative for viral RNA on day five. A total of 10 studies were included in the meta-analysis. Among the 10 studies, five were randomized controlled trials and five were observational studies. Based on the results presented in the meta-analysis, it can be concluded that molnupiravir has a significant impact on reducing all-cause mortality and improving the proportion of patients who test negative for viral RNA on day five. The risk of hospitalization and composite outcome was also lower in molnupiravir-treated patients, although the difference was statistically insignificant. The subgroup analysis showed consistent results across all subgroups, indicating that the effect of molnupiravir is consistent regardless of patient characteristics. |
format | Online Article Text |
id | pubmed-10239651 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-102396512023-06-05 Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis Benaicha, Karima Khenhrani, Raja Ram Veer, Maha Devi, Sapna Shahbaz, Usman Salah, Qais M Hammad, Mostafa Palleti, Sujith K Cureus Family/General Practice The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or moderate COVID-19 patients. This meta-analysis was reported according to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Two authors independently performed a comprehensive search for relevant studies in PubMed, Cochrane Library, and Web of Science. The keywords used to search for relevant records were “Molnupiravir,” “COVID-19,” and “efficacy.” This meta-analysis included studies that compared the effectiveness of molnupiravir with a placebo for COVID-19 treatment. The primary outcome assessed in this meta-analysis was the composite of hospitalization and all-cause mortality (30 days). In addition, we assessed all-cause mortality and hospitalization separately and the number of patients who tested negative for viral RNA on day five. A total of 10 studies were included in the meta-analysis. Among the 10 studies, five were randomized controlled trials and five were observational studies. Based on the results presented in the meta-analysis, it can be concluded that molnupiravir has a significant impact on reducing all-cause mortality and improving the proportion of patients who test negative for viral RNA on day five. The risk of hospitalization and composite outcome was also lower in molnupiravir-treated patients, although the difference was statistically insignificant. The subgroup analysis showed consistent results across all subgroups, indicating that the effect of molnupiravir is consistent regardless of patient characteristics. Cureus 2023-05-05 /pmc/articles/PMC10239651/ /pubmed/37284377 http://dx.doi.org/10.7759/cureus.38586 Text en Copyright © 2023, Benaicha et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Family/General Practice Benaicha, Karima Khenhrani, Raja Ram Veer, Maha Devi, Sapna Shahbaz, Usman Salah, Qais M Hammad, Mostafa Palleti, Sujith K Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis |
title | Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis |
title_full | Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis |
title_fullStr | Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis |
title_full_unstemmed | Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis |
title_short | Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis |
title_sort | efficacy of molnupiravir for the treatment of mild or moderate covid-19 in adults: a meta-analysis |
topic | Family/General Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239651/ https://www.ncbi.nlm.nih.gov/pubmed/37284377 http://dx.doi.org/10.7759/cureus.38586 |
work_keys_str_mv | AT benaichakarima efficacyofmolnupiravirforthetreatmentofmildormoderatecovid19inadultsametaanalysis AT khenhranirajaram efficacyofmolnupiravirforthetreatmentofmildormoderatecovid19inadultsametaanalysis AT veermaha efficacyofmolnupiravirforthetreatmentofmildormoderatecovid19inadultsametaanalysis AT devisapna efficacyofmolnupiravirforthetreatmentofmildormoderatecovid19inadultsametaanalysis AT shahbazusman efficacyofmolnupiravirforthetreatmentofmildormoderatecovid19inadultsametaanalysis AT salahqaism efficacyofmolnupiravirforthetreatmentofmildormoderatecovid19inadultsametaanalysis AT hammadmostafa efficacyofmolnupiravirforthetreatmentofmildormoderatecovid19inadultsametaanalysis AT palletisujithk efficacyofmolnupiravirforthetreatmentofmildormoderatecovid19inadultsametaanalysis |